cyrilzakka/clinical-trials huggingface dataset:
Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Cesarean Section

To evaluate the efficacy of lidocaine patch applied around wound in reduction of postoperative pain and illus compared to intravenous lidocaine infusion and placebo after cesarean section.

The use of lidocaine as a local anesthetic is a common and widely used in practice. Lidocaine patches can be used for localized pain control and can be placed every 24 hours. The use of lidocaine patches in post-operative patients has been reported in one case report in obstetric literature. There is one study that reports decreased immediate postoperative pain when lidocaine patches were placed at laparoscopic port sites following gynecologic surgery as measured by visual analog scale score and the Prince Henry and 5-point verbal rating pain scale . There have been no studies looking at the impact of lidocaine patches in obstetric surgical procedures, specifically cesarean sections.

Eligibility Criteria:
Inclusion Criteria:

* Female
* Primary or secondary cesarean delivery
* Able to consent to research study

Exclusion Criteria:

* 3 or more prior cesarean deliveries
* History of abdominoplasty
* History of abdominal hernia repair with mesh
* Allergy to lidocaine
* Allergy to adhesives in medical tape
* Women who received general anesthesia for their cesarean delivery
* Women with active substance abuse
* Women methadone or suboxone for a history of opiate abuse
Acute Kidney Injury in Major Abdominal Surgery: Retrospective Study of 501 Patients

Retrospective study that aims to examine the presence of acute kidney injury (AKI) during major abdominal surgery, non- cardiac surgery. Using clinical and biochemical data in order to establish AKI frequency and risk factors.

Ethical approval was submitted and approved by the regional ethical committee, Etisk prövningsnämnd Uppsala, # 2017/418.

Patients were selected from the time span of april 2016 to september 2017. The investigators identified 499 patients that had undergone any of the selected procedures. The procedures were, pancreatic resection, HIPEC surgery in colorectal setting, gynecological debulking in metastasized ovarian cancer, and liver resection.

The risk of acute kidney injury (AKI) by the KDIGO definition during the postoperative period will be estimated in the group as a whole, and for each type of surgery separately. In addition the data will be stratified by sex to investigate systematic gender disparities or physiological differences. Length of stay, thirty day and sixty day mortality will secondary endpoints.

Eligibility Criteria:
Inclusion Criteria:

Any of the selected procedures.

Exclusion Criteria:

Patient has expressed his or her will to nor participate in any study.
Evaluation of Placenta Maturity by the Sonographic Textures

The aim of this study is to evaluate placenta maturity by the sonographic textures.The evaluation of placenta maturity by the sonographic textures is related to anticipative pregnancy and actual pregnancy . By analyzing this theory, the investigators want to bring up another objective and accurate analysis method in order to provide information for the evaluation of clinical trials.


Eligibility Criteria:
Inclusion Criteria:

* pregnant women
* Placenta Maturity by the Sonographic Textures

Exclusion Criteria:

* intrauterine-growth retardation(IUGR)
* Pre-eclampsia
* Higher Blood Pressure
* Fetal Distress during a labor
Prospective Data Collection on Cementless Oxford Partial Knee

Prospective data collection on clinical and radiographic outcomes of Cementless oxford Partial Knee.

Prospective radiographic and clinical data collection on outcomes of Cementless oxford Partial Knee. Screened radiographs are taken postoperatively and after 12 months. Oxford Knee Scores, SF12 Health Questionnaires and American Knee Society Radiographic Assessment are taken at 12 month follow-up.

Eligibility Criteria:
Inclusion Criteria:

1. Patients undergoing primary knee arthroplasty
2. Patients with one of the following primary diagnoses in the medial compartment of the knee:

   * Osteoarthritis,
   * Avascular necrosis

Exclusion criteria:

1. Inability to co-operate with and complete the study.
2. Inadequate fixation of cementless components. If either before or after randomization the surgeon feels that cementless fixation is inadequate, cemented components should be inserted.
Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of Epilepsy

Low therapeutic index of established antiepileptic drugs (AEDs) coupled with better understanding of the pathophysiology of seizure has encouraged the development of several novel AEDs. The conventional antiepileptics like phenytoin, phenobarbitone, valproate and carbamazepine and newer antiepileptics like levetiracetam. are used for epilepsy. AEDs induce potentially toxic effects over a period of time which remains undetermined over very long time. Earlier studies in this regard, states uneven results about hematological (Hb%, blood cell count etc.) toxicity of AEDs.

Epilepsy is a chronic neurologic disease that is considered the most common neurological diseases in the world and comes third after cerebrovascular and Alzheimer's disease. Epilepsy is a disorder characterized by a long-term tendency to cause epileptic seizures due to abnormal electrical activity in the brain with neurological, cognitive, psychological and social consequences . However, it is not a single disease entity but it is a collection of different kinds of seizures resulting from several mechanisms and different cause. The aim of epilepsy management is complete seizures cessation and maintenance of a good quality of life, which is affected not only by the epileptic attacks but also by the adverse effect of the drugs used .Levetiracetam (LEV) is a relatively new, broad-spectrum AED that has seen extensive use during recent years . Its mechanism of action is not completely known, but differs from those of other AEDs. LEV is described as being well tolerated, and the most common adverse effects are generally mild . Studies evaluating the effect of levetiracetam on hematological parameters have reported a spectrum of hematological abnormalities that ranges from mild thrombocytopenia or neutropenia to anemia, red cell aplasia, until bone marrow failure. Fortunately, potentially fatal hematological disorders such as aplastic anemia are very rare.

Eligibility Criteria:
Inclusion Criteria: Adult Epileptic patients of both genders aged \>18 years on mono-therapy of levetiracetam anti-epileptic drug treatment for at least six months.

Exclusion Criteria:

1. Patients were on treatment for less than six months.
2. Patients had other conditions besides epilepsy that could affect blood parameters.
3. patients on treatment with other antiepileptic medications besides levetiracetam.
Current Trend of Epidemiology of Psychiatric Emergency and the Stress of Duty Psychiatric Resident

Agitation, paranoia, and suicide risk of the psychiatric patients made them difficult to be managed when they visited medical emergency services. The prolonged waiting time at medical emergency services and the stigmatization of psychiatric medicine also made the psychiatric emergency services full of challenges. However, in recent years, the random killings, celebrity suicide and other major social events attracted much attention to the emergency psychiatry.

Following the establishment of the National Health Insurance, the law of mandatory admission, and the prevalence change of all psychiatric diseases, we are now dealing with totally different types of emergent psychiatric conditions, i.e., depression and suicide. However, the real epidemiological data need to be updated. Psychiatric emergency is one of the entrances of the psychiatric network. A comprehensive review of the psychiatric emergency would be needed for the base of further research.

This study is aimed to investigate the prevalence of psychiatric diagnosis of patients who came to Emergency Department of National Taiwan University Hospital and needed a psychiatric consultation. The epidemiological data will be compared to those collected 30 years ago in the same hospital to examine the 30-year trend. On the other hand, the visiting time and the staying time will be analyzed. The stress of on-duty and the contributing factors will be assessed by a 2-hour in-depth interview with psychiatric residents.


Eligibility Criteria:
Inclusion Criteria:

* Psychiatric resident in NTUH

Exclusion Criteria:

* Major psychiatric illness
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone.

PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.

Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT alone for 12 weeks (AZT monotherapy arm eliminated per 1/19/96 amendment). All patients at a given dose level of HBY 097 must be enrolled and adequate safety data obtained before escalation in subsequent patients begins. Additional patients are entered at the optimal dose of HBY 097. Patients are evaluated weekly for the first 4 weeks and then every 2 weeks for the next 9 weeks.

PER AMENDMENT: Enrollment to the lowest dose cohort is completed.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Treatment for opportunistic infection that develops on study.

Recommended:

* PCP prophylaxis if CD4 count falls below 200 cells/mm3.

Patients must have:

* HIV infection.
* CD4 count 200 - 500 cells/mm3.
* HIV-1 RNA PCR value of 10000 copies/ml or higher.
* Asymptomatic or mildly symptomatic disease.
* No past or current AIDS-defining event.
* Consent of parent or guardian if less than legal age of consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Endocrine, hepatic, renal, or gastrointestinal disease.
* Cardiovascular conduction disease.
* Concomitant medical illness that may complicate study conduct or interpretation of results.
* Other factors that may interfere with patient compliance.

Concurrent Medication:

Excluded:

* Antiretroviral agents other than study drugs.
* Oral contraceptives.
* Cytotoxic chemotherapy.
* Immunomodulators.
* Antiproliferative agents.
* Corticosteroids.
* Anabolic steroids.
* Estrogens.
* Quinoxaline derivatives.

Concurrent Treatment:

Excluded:

* Radiation therapy.

Patients with the following prior conditions are excluded:

* History of hypersensitivity to quinoxaline derivatives or intolerance to AZT.
* History of cardiovascular conduction disease.
* Prior participation in this study or any study using HBY 097.
* Recent use of a drug that interferes with drug metabolism, absorption, distribution, or excretion.
* History of thyroid disease.

Prior Medication:

Excluded at any time:

Prior non-nucleoside reverse transcriptase inhibitors.

Excluded within 30 days prior to study entry:

* Any antiretroviral therapy.
* Oral contraceptives.
* Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons.
* Cytotoxic chemotherapeutic agents.
* Other investigational drugs.

Excluded within 6 months prior to study entry:

Immunotherapeutic vaccine.

Prior Treatment:

Excluded within 30 days prior to study entry:

* Radiation therapy.
* An experimental device. Current ethanol or illicit drug abuse.
Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy

the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy

eligibility criteria: functional constipation,functional diarrhea，irritable bowel syndrome

Eligibility Criteria:
Inclusion Criteria:

* function constipation function diarrhea

Exclusion Criteria:

* not function constipation not function diarrhea
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients

Molecular analysis identifies residual disease by overcoming the sensitivity of imaging methods and therefore has the potential for integrating with therapy provided by FDG-PET alone. It is a well known fact that tumor DNA circulating in plasma (ctDNA) reflects the mutational profile of tumor cells and can be used to non-invasively detect specific mutations of Hodgkin's lymphoma without the need for microdissecting the histological sample.

A clinical need, not yet met for the Hodgkin lymphoma disease, brings about the early and accurate identification of chemo-refractory patients who require stepping up of treatment as also, patients with good prognosis receiving treatment de-escalation.Molecular methods identify residual disease by overcoming the sensitivity of imaging methods and therefore have the potential to integrate the response to therapy provided by FDG-PET alone.

ctDNA modification from the basal time point to the interim can be used as a predictor of response to the ABVD scheme and as a complement to the interim-PET in the possible variation of the therapeutic schedule.

Clinical data and peripheral blood samples (20 ml in EDTA tubes and 20 ml in Cell-Free DNA BCT tubes) will be collected during the clinico/laboratory visits that are planned as per clinical routine at the time of diagnosis, at each cycle of chemotherapy, at the time of interim PET/CT, at the time of end of treatment PET/CT and during follow up.

Eligibility Criteria:
Inclusion Criteria:

* Male or female adults 18 years or older
* Documented diagnosis of Hodgkin lymphoma (both classic and nodular predominant lymphocytes subtype) according to 2016 WHO classification
* Willing and able to comply with scheduled study procedures
* Evidence of a signed informed consent
* ECOG performance status 0-2 (or 3, if disease related)
Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy

Along structural IgA abnormalities, hyperproduction of IgA is thought to play a role in the pathogenesis of primary IgA nephropathy. CD4+CD25+Fox3P regulatory T cells are instrumental in suppressing adaptative immune responses, including B cells production of immunoglobulins. We, the researchers at Centre Hospitalier Universitaire de Saine Etienne, will test the hypothesis that IgA production in patients with IgA nephropathy is dysregulated because of a quantitative and/or qualitative defect of CD4+CD25+FoxP3+ regulatory T cells.


Eligibility Criteria:
Inclusion Criteria:

* Patients with pathogenesis of Berger's disease confirmed by renal biopsy
* Glomerular filtration \> 60 ml/min/1,73m2
* Written informed consent
* Patient affiliated to social insurance

Exclusion Criteria:

* Immunosuppressor treatment within 6 months before the study inclusion
* Clinical infection within 2 months before the study inclusion
* C-reactive protein (CRP) \> 10 mgL-1
The Effect of Reiki and EFT on Symptom Burden, Disease Adaptation, Vital Signs and Catheter-Related Pain in HD Patients

Objective: This study was conducted to evaluate the effect of reiki and emotional release technique (EFT) on symptom burden, disease adaptation, vital signs and catheter-related pain in haemodialysis patients.

Method: The study was conducted as a pretest-posttest randomised controlled experimental research model. The study was conducted in two haemodialysis units in Bingöl province between September 2023 and December 2024. The population of the study consisted of all patients receiving treatment in haemodialysis units, and the sample consisted of 96 patients (Reiki group =32, EFT group =32 and control group =32 people) determined by power analysis. "Dialysis symptom index", " Tee end-stage renal failure adjustment scale", "Vital signs follow-up form" and "Visual analogue scale" were used for data collection.

During the research process, 8 sessions of reiki and EFT were applied to the patients in the experimental groups, while the patients in the control group continued to receive routine care practices.

Eligibility Criteria:
Inclusion Criteria:

* To be over 18 years old,
* To agree to participate in the research,
* To be literate,
* To be able to communicate verbally,
* Receiving three sessions of outpatient haemodialysis (HD) treatment per week in the same institution,
* Active use of the fistula,
* No impairment in mental and cognitive functions,
* Receiving HD therapy for at least three months (to be considered a chronic HD programme)

Exclusion Criteria:

* Refusal to participate in research,
* Receiving peritoneal dialysis,
* To have a central venous catheter,
* A psychiatric disorder diagnosed by a psychiatrist,
* To withdraw from the investigation,
* Losing your life in the process of work,
* Change of institution or city,
Effects on Neuromuscular Function After Dry Needling in Myofascial Trigger Points in the Gastrocnemius Muscles

Trigger points (TrPs) are a common musculoskeletal cause of local and referred muscle pain, as well as local inflammation in the muscle and fascia. From a clinical and sensory viewpoint, TrPs may be classified as active or latent. The principal difference is the reproduction of symptoms experienced by an individual (active) with or without stimulation. Local and referred pain elicited from latent TrPs may be transient in duration upon stimulation, and latent TrPs may be present without spontaneous symptoms.

Both active and latent TrPs induce motor dysfunctions such as stiffness, restricted range of motion, and accelerated fatigability in the affected muscle. The interrater reliability of manual identification of latent TrPs in the calf muscles has been found to range from small to moderate. The clinical relevance of latent TrPs has increased in the last decade,4 and some studies have investigated the effects of treating them. Among all manual therapies targeted to latent TrPs, ischemic compression, or TrP pressure release, is the most commonly used. Although TrPs may affect any muscle, the gastrocnemius muscle may be the most susceptible in the lower extremity to developing them. It has been reported that 13% to 30% of the asymptomatic population has latent TrPs in these muscles, and their presence may affect sport practice.

The purpose of this study will be to evaluate changes in neuromuscular function, pain perception, and basic physical properties in myofascial trigger points (TrPs) after a single treatment session of dry needling in the gastrocnemius muscle.

A randomized within-participant clinical trial with a blinded assessor will be conducted. 50 asymptomatic volunteers (100 gastrocnemius-muscle) with MrPs gastrocnemius-muscle TrPs will bilaterally explored. Each extremity will be randomly assigned to the control group (no treatment) or the experimental group (60 seconds of dry needling over each TrP). Neuromuscular function of the gastrocnemius muscle will be assessed using a MyotonPro and a tensiomyography. Muscle flexibility will be analyzed using the lunge test and the passive ankle range of motion. The strength will be determined with a handheld dynamometer (MicroFET2). Pain perception will be analyzed with a 0-to-10 numerical pain rating scale and determination of pressure pain thresholds over each latent TrP.


Eligibility Criteria:
Inclusion Criteria:

* A TrP will be diagnosed using the following criteria: palpable taut band, presence of a painful spot in the taut band, and referred pain on palpation of the spot.

Exclusion Criteria:

* Participants were excluded if they reported any pain symptoms in the lower extremities in the previous year.
* They were also excluded if they presented previous surgical interventions, previous lower-extremity injury, any underlying medical disease, pregnancy, or muscle soreness after vigorous exercise.
Effect of Kinesiotaping on Muscle Activity

The aim of the investigator's study is to analyze the effect of kinesiotaping (KT) on the electrical activity of the muscle by using time and frequency domain analysis of the electromyography (EMG) signals.

The kinesiotaping (KT) is a taping technique that is commonly used to improve muscle performance and facilitate or inhibit muscle activity in rehabilitation. A study reported that KT application did not change electrical activity in the early period (immediately after KT, 5th and 10 minutes after KT). However, another study showed that EMG activity increased 24 hours after KT application. A study revealed that the KT produced more EMG activity compare to placebo taping. In conclusion, the effect of KT on electrical muscular activity was arguable in the literature.

Eligibility Criteria:
Inclusion Criteria:

* To be right-handed-dominant
* To have normal or corrected vision
* To have no formal history of any resistance training.

Exclusion Criteria:

* To have history of neurological or recent musculoskeletal injury
Patient Comfort With Vascular Closure

The purpose of this research study is to collect information on the amount of discomfort patients experience with one of two different vascular blood vessel closure devices, the MynxM5 Vascular Closure Device and the Angio-Seal Evolution Vascular Closure Device.

The traditional, standard technique of achieving femoral artery hemostasis following diagnostic and interventional catheterization procedures requires compression methods such as manual pressure or clamps held at the puncture site for 10 to 30 minutes, or even longer depending on sheath size and anticoagulation status. This traditional method can be associated with patient discomfort as well as prolonged bed rest, ambulation and hospital discharge.

Over the past decade, Vascular Closure Devices (VCDs), which include collagen hemostasis devices, percutaneous suture-mediated closure devices and metallic clips, have emerged as a novel means for reducing time to hemostasis and ambulation following catheterization procedures performed utilizing femoral arterial access. Previous studies with commercially available VCDs have shown that the reduction in time to hemostasis and time to ambulation and discharge have also led to increased patient satisfaction over manual compression.

The MynxM5 Vascular Closure Device received FDA approval on April 8, 2009. Like the Mynx 6/7F Vascular Closure Device, which received FDA approval on May 16, 2007, both are designed to achieve femoral artery hemostasis via delivery of an extravascular, water-soluble synthetic sealant which expands upon contact with subcutaneous fluids to seal the arteriotomy. In theory, the lack of pressure needed to clamp, suture, clip or cinch, which is required with intravascular closure devices, may provide an advantage in regards to increased patient comfort during closure device deployment when using the Mynx.

Although VCDs have demonstrated an increase in patient comfort and satisfaction over manual compression, little data exists regarding patient comfort when comparing different closure devices. This study is designed to evaluate patient comfort between the MynxM5 and Angio-Seal Evolution Vascular Closure Devices.

Eligibility Criteria:
Inclusion Criteria:

* Patient is \>18 years of age
* Patient has been informed and understands the nature of the study and provides written Informed Consent approved by the appropriate Institutional Review Board prior to enrollment
* Patient has been trained and understands the use of the 0-10 Visual Analogue Scale as an assessment of patient pain
* Patient is scheduled to undergo a diagnostic endovascular procedure involving percutaneous access through the common femoral artery

Exclusion Criteria:

* Per Mynx and Angio-Seal Instructions for Use
* Patient has a documented psychiatric disorder (e.g. major depression, anxiety)
* Patient has a documented chronic pain condition requiring daily treatment
* Patient carries the diagnoses of a known bleeding disorder
* Intraprocedural Exclusion Criteria: Patient has a baseline ipsilateral groin pain rating of \>1 on the 0-10 Visual Analog Scale prior to closure device deployment